Skip to main content
main-content

The independent medical news service

20-06-2022 | Oncology | News | Article

Lorlatinib benefits extend to NSCLC patients with brain metastases

Patients with advanced ALK-positive non-small-cell lung cancer derive prolonged progression-free survival from first-line treatment with lorlatinib regardless of the presence of brain metastases, post-hoc analyses indicate.

08-06-2022 | Oncology | News | Article

Lung-MAP: Post-immunotherapy ramucirumab plus pembrolizumab improves NSCLC survival

Ramucirumab plus pembrolizumab significantly improves overall survival versus standard of care in people with advanced non-small-cell lung cancer previously treated with immunotherapy and chemotherapy, phase 2 Lung-MAP Protocol substudy data show.

07-06-2022 | Oncology | News | Article

NADIM II validates use of neoadjuvant nivolumab–chemo use in stage IIIA–B NSCLC

The neoadjuvant combination of nivolumab and chemotherapy elicits a significantly higher pathologic complete response rate than chemotherapy alone in people with resectable stage IIIA–B non-small-cell lung cancer, shows the phase 2 NADIM II study.

06-06-2022 | Oncology | News | Article

Acetaminophen may blunt ICI response in people with cancer

French researchers have identified an association between detectable plasma levels of acetaminophen and poor outcomes in people receiving immune checkpoint inhibitors for advanced cancer.

06-06-2022 | Oncology | News | Article

SKYSCRAPER-02: Add-on tiragolumab ineffective in extensive-stage SCLC

Adding tiragolumab to atezolizumab plus carboplatin and etoposide provides no additional progression-free or overall survival benefit to patients with untreated extensive-stage small-cell lung cancer, phase 3 study data show.

04-06-2022 | Oncology | News | Article

Amivantamab updates confirm NSCLC efficacy for certain patients

Fresh findings from the phase 1 CHRYSALIS and CHRYSALIS-2 trials have been presented at the 2022 ASCO Annual Meeting, adding support for the use of amivantamab in certain groups of patients with advanced non-small-cell lung cancer.